)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Travere Therapeutics
Travere Therapeutics (TVTX) investor relations material
Travere Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary4 May, 2026
Executive summary
FILSPARI achieved first full FDA approval for FSGS in April 2026 and previously for IgAN in September 2024, expanding its addressable U.S. patient population to over 100,000 and driving record demand and sales growth.
FILSPARI remains the most prescribed FDA-approved therapy for IgAN and the only approved therapy for FSGS, with 993 new patient start forms in Q1 2026 and strong payer coverage.
Pegtibatinase Phase 3 HARMONY Study for HCU restarted in April 2026, with topline data expected in the second half of 2027.
Received $57.5 million in milestone payments from CSL Vifor, $10.2 million from Chugai, and $25 million from Mirum Pharmaceuticals.
Strategic partnerships with CSL Vifor and Chugai provide global access and up to $910 million in potential milestone payments.
Financial highlights
Q1 2026 total revenue was $127.2 million, up from $81.7 million in Q1 2025, driven by FILSPARI's U.S. net product sales of $105.2 million, an 88% year-over-year increase.
THIOLA and Tiopronin products contributed $19.3 million in U.S. net product sales.
Non-GAAP adjusted net income was $4.1 million ($0.05/share), versus a net loss of $16.9 million in Q1 2025; GAAP net loss narrowed to $37.1 million ($0.40/share) from $41.2 million.
Cash, cash equivalents, and marketable securities totaled $264.7 million as of March 31, 2026, with $316 million in convertible notes due 2029.
Gross margin for Q1 2026 was approximately 80% on $124.5 million in sales.
Outlook and guidance
FILSPARI is expected to see continued strong demand in IgAN and rapid uptake in FSGS, supported by evolving KDIGO guidelines and only ~10% market penetration in IgAN.
Topline results from the HARMONY Study of pegtibatinase are anticipated in the second half of 2027.
Management expects available cash and investments to fund operations beyond the next 12 months.
Anticipates milestone and royalty payments from CSL Vifor and Chugai for global FILSPARI access.
FSGS launch uptake and patient start form trends
Sustainability of non-GAAP net income in 2026
R&D expense outlook for HARMONY study restart
Clarify FSGS eligibility and education strategy
FILSPARI positioning versus B-cell competitors
Pegtibatinase HCU endpoint regulatory alignment
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Travere Therapeutics
- FILSPARI drives rare kidney disease leadership, with pipeline and global growth fueling future value.TVTX
Corporate presentation4 May 2026 - FILSPARI is FDA-approved for FSGS without nephrotic syndrome, showing strong efficacy and safety.TVTXStudy update21 Apr 2026
- FILSPARI's record sales and pipeline progress drive robust growth and future potential.TVTXQ4 202513 Apr 2026
- Proxy covers director elections, equity plan, executive pay, auditor, and governance best practices.TVTXProxy filing6 Apr 2026
- Annual meeting to vote on directors, equity plan expansion, executive pay, and auditor ratification.TVTXProxy filing6 Apr 2026
- FILSPARI drives growth in rare kidney diseases, with FSGS approval and HCU trial restart on track.TVTXGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- FILSPARI's strong launch and anticipated label expansion drive growth in rare kidney disease.TVTXH.C. Wainwright 3rd Annual Kidney Virtual Conference3 Feb 2026
- FILSPARI's record Q2 sales and regulatory progress position it for accelerated global growth.TVTXQ2 20242 Feb 2026
- FILSPARI is set for broader use as guidelines evolve and full FDA approval nears.TVTXCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026
Next Travere Therapeutics earnings date
Bank of America Global Healthcare Conference 202613 May, 2026
Travere Therapeutics
Next Travere Therapeutics earnings date
Bank of America Global Healthcare Conference 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage